Skip to content

Study Protocol for the Median Effective Dose and Clinical Efficacy of Continuous Propofol Infusion Combined with Esketamine in Elderly Patients Undergoing Colorectal Polyp ESD Surgery

The Median Effective Dose and Clinical Efficacy of Continuous Propofol Infusion Combined with Esketamine in Elderly Patients Undergoing Colorectal Polyp ESD Surgery

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500102533
Enrollment
Unknown
Registered
2025-05-15
Start date
2025-05-15
Completion date
Unknown
Last updated
2025-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Polyp

Interventions

A:Intravenous injection of propofol 0.3mg/kg + esketamine 0.2mg/kg,The continuous pump infusion adopts the sequential method: the Dixon sequential method is used for the test. The initial dose of the
B:Intravenous injection of propofol 0.3mg/kg,The continuous pump infusion adopts the sequential method: the Dixon sequential method is used for the test. The initial dose of the first patient to recei

Sponsors

Shanghai Xuhui Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Age 65-75 years old; 2.Patients who are planning to undergo ESD for colon polyps; 3.The operation time is less than 1 hour; 4.American Society of Anesthesiologists (ASA) grade I-II; 5.Body Mass Index (BMI) 20-25. 6.Mallampati grade I-II.

Exclusion criteria

Exclusion criteria: 1.Patients with severe systemic diseases, such as liver and kidney dysfunction, cardiovascular and cerebrovascular diseases, immune system diseases, etc. 2.Patients with alcoholism, drug dependence, history of mental illness or neurological diseases (Alzheimer's disease, stroke and abnormal psychology); 3.Patients with surgical procedures changed due to patient reasons; 4.Patients who are allergic to esketamine or propofol and any ingredients in their formulations. 5.Patients with upper airway abnormalities, respiratory insufficiency or sleep apnea that may cause dyspnea.

Design outcomes

Primary

MeasureTime frame
The Dosage of cyclopofol while Postive reaction occures;

Secondary

MeasureTime frame
heart rate;MAP;SPO2;Anesthesia onset time;Total intraoperative dose of propofol;Dosage of vasoactive drugs during surgery;wake time;

Countries

China

Contacts

Public ContactIlyar Mamtili

Shanghai Xuhui Central Hospital

ilyar214@foxmail.com+86 139 1830 9544

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026